Please login to the form below

Not currently logged in
Email:
Password:

UniQure

This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.

UK’s CMA clears Roche’s $4.3bn takeover of Spark

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.

Latest news

More from news
Approximately 12 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera. ... The success or failure of Bluebird will be closely watched

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for

  • Pharma deals in April 2015 Pharma deals in April 2015

    BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution Solaris Health looks at the gene therapy revolution

    There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics